Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93

Benzinga Newsdesk www.benzinga.com Negative 87.6%

Neg 87.6% Neu 0% Pos 0%

Wells Fargo analyst Benjamin Burnett maintains PTC Therapeutics (NASDAQ:PTCT) with a Overweight and lowers the price target from $95 to $93.